BTIG analyst Mark Massaro maintained a Buy rating on Lucid Diagnostics (LUCD – Research Report) yesterday and set a price target of $2.50. The company’s shares closed last Friday at $1.41.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Personalis, and SOPHiA GENETICS. According to TipRanks, Massaro has an average return of -15.6% and a 33.00% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lucid Diagnostics with a $4.06 average price target.
See Insiders’ Hot Stocks on TipRanks >>
LUCD market cap is currently $62.98M and has a P/E ratio of -1.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lucid Diagnostics (LUCD) Company Description:
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
Read More on LUCD:
- PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
- PAVmed announces 1-for-15 reverse stock split
- Lucid Diagnostics price target lowered to $2.50 from $3 at BTIG
- Lucid Diagnostics expands executive team
- Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
